Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06387420
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-29
First Post:
2024-04-24
Brief Title:
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
Sponsor:
Akeso
Organization:
Akeso
Study Overview
Official Title:
A Phase 1b2 Study of AK117 Anti-CD47 Antibody in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1b2 study All patients are diagnosed with Acute Myeloid Leukemia AML Eastern Cooperative Oncology Group ECOG performance status 0-3 The purpose of this study is to evaluate the safety and efficacy of AK117 azacitidine venetoclax in subjects with AML
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None